Antithrombotic therapy in patients with ACS and atrial fibrillation: A challenge in clinical practice

Atrial fibrillation (AF) is the most commonly encountered cardiac arrhythmia in clinical practice. Furthermore, the incidence of AF steadily increases with advancing age, and AF is also a frequently diagnosed complication following ACS. The management of patients with AF and ACS who require triple therapy (currently defined as aspirin plus clopidogrel and warfarin) is challenging. The aim of this article is to review the risk-benefit trade-off between the ischemic and bleeding events that are associated with the various antithrombotic combination therapies used to treat this high-risk patient population.

Duke Scholars

Author Renato Delascio Lopes Medicine, Cardiology